New targeted therapy improved survival for patients with KRAS-mutated lung cancer

Patients with antecedently treated precocious KRAS G12C-mutant non-small compartment lung crab (NSCLC) lived importantly longer and saw improved illness power erstwhile treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.